Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Ends Year With Set of Straight Noes For PRIME Applicants

Executive Summary

The European Medicines Agency rejected all seven eligibility requests for its priority medicines scheme that it reviewed in December.

You may also be interested in...



PRIME Dry Spell Continues At EMA

Developers of medicines that benefit from the European Medicines Agency’s priority medicines scheme can expect to be eligible for accelerated assessment when they eventually file for approval. But there have been no new entries to the scheme for two months now.

A Whistle-Stop Tour of 2017 – From An EU Regulatory Point Of View

This past year was a busy one for regulators and regulated alike in the EU. We take a look at some of the key events from 2017.

A Whistle-Stop Tour of 2017 – From An EU Regulatory Point Of View

This past year was a busy one for regulators and regulated alike in the EU. We take a look at some of the key events from 2017.

Related Content

Topics

UsernamePublicRestriction

Register

PS122205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel